Canagliflozin in combination therapy for treating type 2 diabetes

Review proposal consultation

Stakeholder matrix (PDF 259 KB)

Review proposal paper (PDF 296 KB)

Diabetes (type 2) - canagliflozin: equality impact assessment - guidance review (PDF 161 KB)

Diabetes (type 2) - canagliflozin: final appraisal determination information

Diabetes (type 2) - canagliflozin: FAD document (PDF 457 KB)

Diabetes (type 2) - canagliflozin: evaluation report information

Diabetes (type 2) - canagliflozin: evaluation report (PDF 2.06 MB)

Diabetes (type 2) - canagliflozin: appraisal consultation

Diabetes (type 2) - canagliflozin: appraisal consultation document information

Diabetes (type 2) - canagliflozin: evaluation report information

Diabetes (type 2) - canagliflozin: evaluation report (PDF 13.83 MB)

Diabetes (type 2) - canagliflozin: Equality Impact Assessment - scoping (PDF 123 KB)

Diabetes (type 2) - canagliflozin: response to consultee and commentator comments on the draft scope and provisional matrix (PDF 280 KB)

Diabetes (type 2) - canagliflozin: final scope (PDF 40 KB)

Diabetes (type 2) - canagliflozin:final matrix (PDF 53 KB)

Diabetes (type 2) - canagliflozin: draft scope - (pre referral) (PDF 117 KB)

Diabetes (type 2) - canagliflozin: provisional matrix - (pre referral) (PDF 102 KB)